

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Ivins Memorial Hospital 2. 255 North 30th Street Laramie, WY 82072-5195		In accordance with letter dated October 3, 2016 3. License number: 49-15978-01 is amended in its entirety to read as follows:	4. Expiration Date: March 31, 2019 5. Docket No.: 030-10133 Reference No.:
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200	7. Chemical and/or physical form A. Any B. Any	8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. As Needed	9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

49-15978-01

Docket or Reference Number

030-10133

Amendment No. 25

6. Byproduct, source,
and/or special nuclear
material

C. Any byproduct material
identified in 10 CFR
35.400

7. Chemical and/or physical form

C. Sealed Sources (Bard
Brachytherapy, Inc., Model STM
1251; Best Medical International,
Inc. (Formerly Best Industries,
Inc.), Model 2300 Series; Core
Oncology, Inc. (Formerly Mills
Biopharmaceuticals, LLC),
Model I-125 SL or I-125 SH;
International Brachytherapy SA.,
Model OptiSeed103 Model
1032p or Model 1251L; IsoAid,
L.L.C., Model IAI-125A or
IAPd-103A (Advantage™
Pd-103); Medi-Physics,
Inc./Amersham Health, Model
6711(OncoSeed™) or 6733
(EchoSeed™); North American
Scientific, Inc., Model MED3631
or MED3633; Theragenics
Corporation, Model I-Seed
I25.S06 or TheraSeed® Model
200)

8. Maximum amount that licensee
may possess at any one time
under this license

C. 5 curies total

9. Authorized use

C. For any manual brachytherapy
procedure permitted by 10 CFR 35.400.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 255 North 30th Street, Laramie, Wyoming.

11. The Radiation Safety Officer for this license is Jeanne M. Hennemann, M.D.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

49-15978-01

Docket or Reference Number

030-10133

Amendment No. 25

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users, authorized nuclear pharmacists, and/or authorized medical physicists in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)Material and Use

Robert Lawrence Tobin, M.D.

35.400

John D. Purviance, M.D.

35.400

Jeanne M. Hennemann, M.D.

35.100, 35.200

Christine Lauro, M.D.

35.400

13. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:

A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.

B. Notwithstanding Paragraph A of this Condition, sealed sources designed to primarily emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed 3 months.

C. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
49-15978-01

Amendment No. 25

Docket or Reference Number
030-10133

- D. Sealed sources need not be tested if they contain only hydrogen 3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha emitting material.
- E. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
- F. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within 5 days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region IV, 1600 East Lamar Boulevard, Arlington, Texas 76011-4511, ATTN: Director, Division of Nuclear Materials Safety. The report shall specify the source involved, the test results, and corrective action taken.
- G. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or by other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
14. The licensee shall conduct a physical inventory every 6 months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license.
15. Sealed sources containing licensed material shall not be opened or sources removed from detector cells by the licensee, except as specifically authorized.
16. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing financial assurance for decommissioning.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

49-15978-01

Docket or Reference Number

030-10133

Amendment No. 25

17. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
18. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated September 17, 2008 (ML082900601)
 - B. Letter dated October 21, 2008 (ML090150665)
 - C. E-mail dated March 3, 2009 (ML090640901)
 - D. Application dated May 10, 2010 (ML101540472)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

/RA/Date: December 5, 2016

By: _____
Roberto J. Torres, M.S., Senior Health Physicist
Nuclear Materials Branch B
Region IV Arlington, Texas 76011-4511